Clinical Review - Renal colic
Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more
Subsequently, women have been advised to take HRT for as short a time as possible. But follow-up data from the WHI suggests that the increased cancer risk remains even after stopping HRT.
The latest data comes from follow-up of 15,730 postmenopausal women, aged 50-79, who had participated in the WHI study.
Half the women had been taking oestrogen plus progesterone HRT, but stopped the treatment in 2002 when the WHI study was abandoned. The rest of the women had taken placebo.
Follow-up from July 2002 until March 2005, revealed that 281 women who had received HRT went on to develop cancer, compared with 218 who had not received HRT.
Overall, the combined risk of suffering heart disease, stroke, hip fracture or cancer increased by 12 per cent in the HRT group, compared with the placebo group.
Researchers from the University of North Carolina hope the findings can help calculate optional use of HRT.
Comment below and tell us what you think
Quick search - use * for an abbreviated search, eg nico*
Quick search - use * for an abbreviated search, eg nico*
Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more
By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more
Although it is one of the most common autoimmune diseases, Sjogren's syndrome remains underdiagnosed... Read more
Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more
Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more
Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more
Comments
Only registered users may comment. Log in now or register for a free account.